Apathy in Dementia
Conditions
Brief summary
Apathy in dementia prevents successful application of non-pharmacological treatments, accelerates cognitive and functional decline and increases disease-related costs by earlier need for full-time care. Apathy is a distinct entity and occurs independently of other neuropsychiatric syndromes, like depression. Today, there is no high-level evidence for any effective treatment of apathy in AD. In contrast to other neuropsychiatric syndromes in AD, like psychosis and depression, and despite its high prevalence and clinical relevance, apathy has never been the primary outcome in a clinical trial. Basic and clinical research has provided a distinct model of the pathophysiology of apathy with dopamine and norepinephrine as the key neurotransmitter systems involved. The antidepressant Bupropion is a dopamine and norepinephrine reuptake inhibitor. There is evidence from case-series, that Bupropion reduces apathy in patients with organic brain disorders. This study will test the efficacy and safety of Bupropion in the treatment of apathy in AD in a 12-week multicenter doubleblind placebo controlled trial. Secondary endpoints will be quality of life of patients, caregivers' distress, ability of patients to perform activities of daily living,utilization of healthcare resources by patients and by caregivers, and cognitive functions.
Interventions
DRUGElontril
flexible dose of Bupropion 150-300 mg
DRUGplacebo
Sponsors
University Medical Center Goettingen
University of Cologne
Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef
Charite University, Berlin, Germany
Universität Duisburg-Essen
University of Erlangen-Nürnberg
University of Freiburg
Universität des Saarlandes
Johannes Gutenberg University Mainz
Heidelberg University
Philipps University Marburg
Ludwig-Maximilians - University of Munich
University of Rostock
University Hospital Tuebingen
University of Ulm
University Hospital, Bonn
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Mild to moderate Alzheimer's dementia, male and female (NINCDS/ADRDA criteria) * Presence of clinically relevant apathy defined by the Neuropsychiatric Inventory (NPI) apathy item (score of \>/= 4 points) and the Marin/Starkstein criteria for apathy * MMSE: 10-25 * Outpatient status, not institutionalized * Presence of reliable caregiver * Stable treatment with antidementia drugs for at least three months prior to entry or no treatment with antidementia drugs
Exclusion criteria
* Other Dementia (e.g. vascular dementia, Lewy-body dementia, fronto-temporal dementia) * Presence of a clinically relevant depression defined by either the NPI depression item (score \>/= 4 points) or DSM-IV criteria for major depressive episode (with depressed mood) * Alcoholism and Benzodiazepine addiction * Current treatment with antipsychotics and antidepressants (including St. John's wart) * Current treatment with dopaminergic agents or Amantadin * Current treatment with benzodiazepines * Current treatment with MAO inhibitor (Bupropion contraindication) * Known sensibility to Bupropion treatment * Severe psychiatric disease (including hospitalization) in the last 6 months, suicide attempt, acute psychotic symptoms * Severe physical illness, that do not allow a participation in a 12-week period of treatment * Medical history with seizures * Medical history with tumors of the central nervous system * Severe craniocerebral injury and medical history with cerebral substance defect * Clinically relevant renal disease, liver insufficiency * Simultaneous treatment, which reduces the seizure threshold (e.g. antipsychotics, antidepressants, antimalarial agents, Tramadol, Theophyllin, systemic steroids in higher dose, Chinolone, sedative antihistamines) * Simultaneous treatment, which is metabolized through Cytochrom P450-Isoenzym 2D6 (e.g. these beta blockers: Metoprolol, Proanolol, Timolol, Carvediol, Nebivolol, Typ-1C-Antiarrhyhtmics for e.g. Propafenon, Flecinid) (except Donepezil and Galantamin) * Simultaneous treatment with drugs, which may interfere with the metabolization of Bupropion (e.g. Carbamazepin, Phenytoin, Valproat, Ritonavir, Lopinavir) * Diabetes mellitus, which is therapeutically poorly regulated and treated by medication * Treatment with stimulants and appetite depressants * Participation in other clinical trials with in the last 3 months * Suicidal tendency * Known lactose intolerance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Apathy Evaluation Scale (AES) score | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE | 12 weeks |
Countries
Germany
Outcome results
None listed